Rupesh Raina1,2,3, Ronith Chakraborty4,5, Isabelle Mawby4, Nirav Agarwal4, Sidharth Sethi6, Michael Forbes7. 1. Department of Nephrology, Akron Nephrology Associates/Cleveland Clinic Akron General, Akron, OH, USA. rraina@akronchildrens.org. 2. Department of Nephrology, Akron Children's Hospital, Akron, OH, USA. rraina@akronchildrens.org. 3. School of Medicine, Case Western Reserve University, Cleveland, OH, USA. rraina@akronchildrens.org. 4. Department of Nephrology, Akron Nephrology Associates/Cleveland Clinic Akron General, Akron, OH, USA. 5. Department of Nephrology, Akron Children's Hospital, Akron, OH, USA. 6. Pediatric Nephrology, Kidney Institute, Medanta, The Medicity Hospital, Gurgaon, Haryana, India. 7. Director of Clinical Research and Outcomes Analysis, Department of Pediatrics, Akron Children's Hospital, Akron, OH, USA.
Abstract
BACKGROUND AND OBJECTIVES: COVID-19 is responsible for the 2019 novel coronavirus disease pandemic. Despite the vast research about the adult population, there has been little data collected on acute kidney injury (AKI) epidemiology, associated risk factors, treatments, and mortality in pediatric COVID-19 patients admitted to the ICU. AKI is a severe complication of COVID-19 among children and adolescents. METHODS: A comprehensive literature search was conducted in PubMed/MEDLINE and Cochrane Center Trials to find all published literature related to AKI in COVID-19 patients, including incidence and outcomes. RESULTS: Twenty-four studies reporting the outcomes of interest were included. Across all studies, the overall sample size of COVID positive children was 1,247 and the median age of this population was 9.1 years old. Among COVID positive pediatric patients, there was an AKI incidence of 30.51%, with only 0.56% of these patients receiving KRT. The mortality was 2.55% among all COVID positive pediatric patients. The incidence of multisystem inflammatory syndrome in children (MIS-C) among COVID positive patients was 74.29%. CONCLUSION: AKI has shown to be a negative prognostic factor in adult patients with COVID-19 and now also in the pediatric cohort with high incidence and mortality rates. Additionally, our findings show a strong comparison in epidemiology between adult and pediatric COVID-19 patients; however, they need to be confirmed with additional data and studies.
BACKGROUND AND OBJECTIVES:COVID-19 is responsible for the 2019 novel coronavirus disease pandemic. Despite the vast research about the adult population, there has been little data collected on acute kidney injury (AKI) epidemiology, associated risk factors, treatments, and mortality in pediatric COVID-19patients admitted to the ICU. AKI is a severe complication of COVID-19 among children and adolescents. METHODS: A comprehensive literature search was conducted in PubMed/MEDLINE and Cochrane Center Trials to find all published literature related to AKI in COVID-19patients, including incidence and outcomes. RESULTS: Twenty-four studies reporting the outcomes of interest were included. Across all studies, the overall sample size of COVID positive children was 1,247 and the median age of this population was 9.1 years old. Among COVID positive pediatric patients, there was an AKI incidence of 30.51%, with only 0.56% of these patients receiving KRT. The mortality was 2.55% among all COVID positive pediatric patients. The incidence of multisystem inflammatory syndrome in children (MIS-C) among COVID positive patients was 74.29%. CONCLUSION: AKI has shown to be a negative prognostic factor in adult patients with COVID-19 and now also in the pediatric cohort with high incidence and mortality rates. Additionally, our findings show a strong comparison in epidemiology between adult and pediatric COVID-19patients; however, they need to be confirmed with additional data and studies.
Authors: Leora R Feldstein; Erica B Rose; Steven M Horwitz; Jennifer P Collins; Margaret M Newhams; Mary Beth F Son; Jane W Newburger; Lawrence C Kleinman; Sabrina M Heidemann; Amarilis A Martin; Aalok R Singh; Simon Li; Keiko M Tarquinio; Preeti Jaggi; Matthew E Oster; Sheemon P Zackai; Jennifer Gillen; Adam J Ratner; Rowan F Walsh; Julie C Fitzgerald; Michael A Keenaghan; Hussam Alharash; Sule Doymaz; Katharine N Clouser; John S Giuliano; Anjali Gupta; Robert M Parker; Aline B Maddux; Vinod Havalad; Stacy Ramsingh; Hulya Bukulmez; Tamara T Bradford; Lincoln S Smith; Mark W Tenforde; Christopher L Carroll; Becky J Riggs; Shira J Gertz; Ariel Daube; Amanda Lansell; Alvaro Coronado Munoz; Charlotte V Hobbs; Kimberly L Marohn; Natasha B Halasa; Manish M Patel; Adrienne G Randolph Journal: N Engl J Med Date: 2020-06-29 Impact factor: 91.245
Authors: Rachel Harwood; Benjamin Allin; Christine E Jones; Elizabeth Whittaker; Padmanabhan Ramnarayan; Athimalaipet V Ramanan; Musa Kaleem; Robert Tulloh; Mark J Peters; Sarah Almond; Peter J Davis; Michael Levin; Andrew Tometzki; Saul N Faust; Marian Knight; Simon Kenny Journal: Lancet Child Adolesc Health Date: 2020-09-18
Authors: Elizabeth Whittaker; Alasdair Bamford; Julia Kenny; Myrsini Kaforou; Christine E Jones; Priyen Shah; Padmanabhan Ramnarayan; Alain Fraisse; Owen Miller; Patrick Davies; Filip Kucera; Joe Brierley; Marilyn McDougall; Michael Carter; Adriana Tremoulet; Chisato Shimizu; Jethro Herberg; Jane C Burns; Hermione Lyall; Michael Levin Journal: JAMA Date: 2020-07-21 Impact factor: 157.335
Authors: Houda Nassih; Sara Belghmaidi; Rabiy El Qadiry; Ibtissam Hajji; Aicha Bourrahouat; Abdeljalil Moutaouakil; Imane Ait Sab Journal: Glob Pediatr Health Date: 2022-07-22